Dr. David W. Parke III, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Baylor College of Medicine (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 1,282
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: Baylor College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
MN license 56678 · FL license ME109699 · FL license TRN12604 -
Internal Medicine Physician
OK license 25653
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Vitreoretinal Surgery PLLC (23 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,282
- Services billed
- 43,801
- Patients’ average age
- 79
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 33,300 | 94 |
| Injection, aflibercept, 1 mg | 4,240 | 414 |
| Imaging of retina | 3,721 | 1,308 |
| Injection of drug into eye | 2,762 | 687 |
| Injection, ranibizumab, 0.1 mg | 1,251 | 77 |
| Established patient problem focused exam of visual system | 863 | 536 |
| Injection, bevacizumab, 10 mg | 625 | 167 |
| Established patient complete exam of visual system | 584 | 512 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 380 | 39 |
| New patient office or other outpatient visit, 45-59 minutes | 151 | 151 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ketorolac Tromethamine Other prescribers in Minneapolis, MN | 248 |
| Prednisolone Acetate Other prescribers in Minneapolis, MN | 223 |
| Latanoprost Other prescribers in Minneapolis, MN | 136 |
| Neomycin-Polymyxin-Dexameth (neomycin/polymyxin b/dexametha) Other prescribers in Minneapolis, MN | 121 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Minneapolis, MN | 81 |
| Brimonidine Tartrate Other prescribers in Minneapolis, MN | 56 |
| Timolol Maleate Other prescribers in Minneapolis, MN | 50 |
| Atropine Sulfate | 36 |
| Dorzolamide Hcl Other prescribers in Minneapolis, MN | 21 |
| Difluprednate | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 5 companies. The companies reported $318,280 in research payments for these studies, mostly to the institutions running them.
- A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-R…
Apellis Pharmaceuticals, Inc. - Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
Ocular Therapeutix, Inc. - A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy …
Janssen Research & Development, LLC - OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD
Genentech, Inc. - An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Apellis Pharmaceuticals, Inc. - Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies
Janssen Research & Development, LLC - Faricimab DME Long Term Extension Rhone X
Genentech, Inc. - A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy …
Janssen Research & Development, LLC - A phase iii study to evaluate faricimab in patients with central retinal vein occlusion
Genentech, Inc. - VA2 PhIII
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.